In clinical trials, dabrafenib exhibited a similar efficacy as well as side effects for treating advance melanoma with BRAF(V600E) mutation, but better activity on brain metastasis in contrast to vemurafenib[135-137], although no direct comparison between these two inhibitors has been carried out to reach a definitive conclusion. Here, BRAF is linked to melanoma.